Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces that it has received an incredible response from shareholders registering for RCD Personal Shareholder Loyalty Gift. Mr. Raymond C. Dabney is CBIS’ President, CEO, and Co-founder. Registration for the Shareholder Loyalty Gift closed on January 31, 2019, and over 3,500 CBIS shareholders applied and processed via the Company’s portal. With another very large amount of emails to sort and process, inquiring how and where to proceed, fix, and/or confirm, RCD is ready to roll!
“2018 was an important year for Cannabis Science,” stated Mr. Dabney. “I believe the Company is well positioned for growth as a result of our investments in a number of collaborations with leading research institutions and private industry business worldwide. Our objective in 2019 is to build on that success by building on our consortium partnerships and licensing programs for our patents and initiatives.
“We will also begin increasing direct investment opportunities. These opportunities will be designed for the general public to directly invest in a particular project and share in the wealth. Designed to give back to the people who want a tangible investment opportunity to participate in actual asset based projects with real asset growth potential. There are multiple international economic development projects currently underway, upcoming clinical trials, and subsequent formal drug development programs that are all outstanding investment opportunities for the industry.
“Again, these types of investment projects are opening the doors to the public to participate financially and grow with an in-depth pipeline of blockbuster critical ailment and palliative care candidate drugs using the broad strengths of cannabinoids and other natural constituents. While a considerable amount of work remains to be done, I believe we are well on our way. I look forward to sharing our story with our stakeholders at the Black-tie Gala, see you soon!”
Mr. Dabney invites everyone to www.iCannabinoid.com and join in today. Mr. Dabney has begun using it for open discussions to interact and share real-time accurate information. Mr. Dabney already has begun creating ‘Action Group’ discussion forums for various topics on critical ailments, the company’s many drug development initiatives, and the 2019 Cannabis Science Black-Tie Dinner Awards Gala, as well as real-time updates on the RCD Personal Shareholder Loyalty Gift, and other important Company news.
Patients, Doctors, Industry Professionals, Lawyers, Scientists, Activists, Legalization Groups, and many others can use iCannabinoid as an interactive, powerful knowledge center that will contain real-world data on successful treatment stories and clinical study information. iCannabinoid will help enable everyone to better leverage information – research, development, pre-clinical, clinical trials, patient data, etc. – and help Cannabis Science to bring better products to market faster.
All inquiries from sponsors, backers, models, and performers for the 2019 Black-Tie Dinner Awards Gala, are encouraged to go to www.iCannabinoid.com: register and join in the 2019 Black-Tie Awards Gala ‘Action Group’ to help “make that change.”
About Cannabis Science, Inc.
Cannabis Science’s primary objective is to research and develop U.S. Food and Drug Administration (FDA)-approved, cannabinoid-based medicine to fight a number of targeted critical ailments, including various Cancers, Neurological Conditions, PTSD, Sleep Deprivation, Chronic Pain, HIV/AIDS, Autism, Parkinson’s Disease, Epilepsy, Chronic Obstructive Pulmonary Disease (COPD), and others. CBIS and its collaborators are well underway on a number of research projects targeting Lung Cancer, Pancreatic Cancer, Chronic Pelvic Pain, and Oro-bucco-lingual Dyskinesias.
Cannabis Science takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a ‘safe harbor’ for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company’s reports filed with the Securities and Exchange Commission.